Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Mayinglong Pharmaceutical Group Co Ltd
Income from Continuing Operations
Mayinglong Pharmaceutical Group Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
M
|
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
|
Income from Continuing Operations
¥495.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
11%
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Income from Continuing Operations
¥2.9B
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥4.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥4.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Income from Continuing Operations
¥755.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
See Also
What is Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
495.3m
CNY
Based on the financial report for Sep 30, 2023, Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations amounts to 495.3m CNY.
What is Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
11%
Over the last year, the Income from Continuing Operations growth was -4%. The average annual Income from Continuing Operations growth rates for Mayinglong Pharmaceutical Group Co Ltd have been 8% over the past three years , 20% over the past five years , and 11% over the past ten years .